Saltar al contenido
Merck
  • Adenosine receptor expression in an experimental animal model of myocardial infarction with preserved left ventricular ejection fraction.

Adenosine receptor expression in an experimental animal model of myocardial infarction with preserved left ventricular ejection fraction.

Heart and vessels (2013-07-12)
Manuela Cabiati, Alessandro Martino, Letizia Mattii, Chiara Caselli, Tommaso Prescimone, Vincenzo Lionetti, Maria-Aurora Morales, Silvia Del Ry
RESUMEN

Adenosine, a purine nucleoside and a "retaliatory metabolite" in ischemia, is ubiquitous in the body and increases 100-fold during ischemia. Its biological actions are mediated by four adenosine receptors (ARs): A(1), A(2A), A(2B) and A(3). The aim of this study was to determine possible myocardial alterations in AR expression in an experimental animal model of myocardial infarction (MI) with a preserved left ventricular (LV) ejection fraction. LV tissue was collected from sexually mature male farm pigs with MI (n = 6) induced by permanent surgical ligation of the left anterior descending coronary artery and from five healthy pigs (C). mRNA expression of A(1)R, A(2A)R, A(2B)R, A(3)R and TNF-α was determined by real-time PCR in tissue collected from border (BZ) and remote zones (RZ) of the infarcted area and from LV of C. BZ, RZ and samples of C were stained immunohistochemically to investigate A(3)R immunoreaction. After 4 weeks a different regulation of ARs was observed. A(1)R mRNA expression was significantly lower in the infarct regions than in controls (C = 0.75 ± 0.2, BZ = 0.05 ± 0.2, RZ = 0.07 ± 0.02 p = 0.0025, p = 0.0016, C vs. BZ and RZ, respectively). Conversely A(3)R was higher in infarct areas (C = 0.94 ± 0.2, BZ = 2.85 ± 0.5, RZ = 3.48 ± 1.0, p = 0.048 C vs. RZ). No significant differences were observed for A(2A)R (C = 1.58 ± 0.6, BZ = 0.42 ± 0.1, RZ = 1.37 ± 0.6) and A(2B)R (C = 1.66 ± 0.2, BZ = 1.54 ± 0.5, RZ = 1.25 ± 0.4). A(3)R expression was confirmed by immunohistochemical analysis and was principally localized in cardiomyocytes. TNF-α mRNA results were: C 0.41 ± 0.25; BZ 1.60 ± 0.19; RZ 0.17 ± 0.04. The balance between A(1)R and A(3)R as well as between A(2A)R and A(2B)R was consistent with adaptative retaliatory anti-ischemic adenosinergic changes in the infarcted heart with preserved LV function.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cloroformo, contains 100-200 ppm amylenes as stabilizer, ≥99.5%
Sigma-Aldrich
Cloroformo, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains amylenes as stabilizer
Sigma-Aldrich
Cloroformo, suitable for HPLC, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Cloroformo, contains ethanol as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
Cloroformo, ReagentPlus®, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Cloroformo, contains amylenes as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
Cloroformo, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Cloroformo, ACS spectrophotometric grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Cloroformo, biotech. grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Cloroformo, contains ethanol as stabilizer, meets analytical specification of BP, 99-99.4% (GC)
Sigma-Aldrich
Cloroformo, ≥99%, PCR Reagent, contains amylenes as stabilizer
Supelco
Cloroformo, analytical standard
Supelco
Cloroformo, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Cloroformo, anhydrous, contains amylenes as stabilizer, ≥99%
Supelco
Cloroformo, Pharmaceutical Secondary Standard; Certified Reference Material